Physician profile
Kevin Combs
NPI 1164614079
$1,839.80
in general payments reported to CMS, 2019-2025
12 companies · $308 in 2025
The $308 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $495 · 2020: $96.90 · 2023: $76.31 · 2024: $864 · 2025: $308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,248.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $417.62 | 2019-2024 | Spravato |
| Astrazeneca Pharmaceuticals LP | $342.14 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $161.16 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $125.00 | 2024 | Uzedy |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2025 | Cobenfy |
| Inspire Medical Systems, INC. | $112.81 | 2024 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.22 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $98.88 | 2024 | Dupixent |
| Pfizer INC. | $96.90 | 2020 | |
| Amgen INC. | $94.00 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $86.76 | 2025 | Rexulti |
| Novo Nordisk INC | $76.31 | 2023 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Combs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.